These Analysts Increase Their Forecasts On PTC Therapeutics
1. PTC Therapeutics gained FDA approval for SEPHIENCE for PKU treatment. 2. The approval is seen as a major milestone for PKU patients. 3. PTC shares rose 11.7% post-announcement, trading at $49.53. 4. Analysts raised price targets for PTC, signaling strong market confidence. 5. PTC’s management is prepared to launch SEPHIENCE promptly.